Novartis received approval from the European Commission to market the drug everolimus in the treatment of patients with neuroendocrine tumors of the pancreas in an advanced stage.
The authorization is based on the results of Phase III clinical tests have shown that everolimus reduced by 65% the risk of progression of this tumor compared to a placebo.
'A consistent improvement in survival without disease progression was observed with everolimus in each subgroup of patients, including those who have not received chemotherapy earlier', says the Swiss pharmaceutical company.
The decision applies to Brussels 27 member countries of the European Union, plus Iceland and Norway.
How Long Do Smart Plugs Last On Average?
-
A smart plug's longevity is dictated by how gentle and strategic you are
with its use, so knowing its primary enemies helps you avoid common
pitfalls.
54 minutes ago
